1. Topic S7B. The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. CHMP/ICH/423/02;International Council on Harmonisation,2005
2. Clinical and nonclinical evaluation of QT/QTc interval prolongation and proarrhythmic potential – questions and answers. EMA/CHMP/ICH/415588/2020;International Council on Harmonisation E14/S7B Implementation Working Group,2022
3. Towards a structural view of drug binding to hERG K+ channels;Vandenberg;Trends Pharmacol. Sci.,2017
4. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium;Sager;Am. Heart J.,2014
5. An update on the structure of hERG;Butler;Front. Pharmacol.,2020